½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting

»¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

021-54845833/15800441009

Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > Ò»¿¹ > Íÿ¹AGXT¶à¿Ë¡¿¹Ìå

²úÆ·ÖÐÐÄ

×îвúÆ·

  • Íÿ¹AGXT¶à¿Ë¡¿¹Ìå

    ¹æ¸ñ£º
    ¼Û¸ñ£º£¤
    • Æ·ÅÆ : ͨεÉúÎï
    • Ŀ¼ºÅ : TW1422
    • Ó¦Óà : ½öÓÃÓÚ¿ÆÑÐʹÓÃ
    • »õÆÚ : ÏÖ»õ
    • ¹æ¸ñ £º100ul/200ul/25ul
  • ÉÌÆ·ÏêÇé
  • ²Î¿¼ÎÄÏ×
  • ˵Ã÷ÊéÏÂÔØ
  • ÉÌÆ·ÆÀÂÛ0
  • Ïà¹Ø²úÆ·

ÖÐÎÄÃû³Æ£ºÍÿ¹AGXT¶à¿Ë¡¿¹Ìå

Ó¢ÎÄÃû³Æ£º Anti-AGXT rabbit polyclonal antibody

±ð      Ãû£º AGT; PH1; SPT; AGT1; SPAT; TLH6; AGXT1

Ïà¹ØÀà±ð£º Ò»¿¹

´¢      ´æ£º Àä¶³£¨-20¡æ£©

ËÞ      Ö÷£º Rabbit

¿¹      Ô­£º AGXT

·´Ó¦ÖÖÊô£º Human, Mouse, Rat

±ê ¼Ç Î Unconjugate

¿Ë¡ÀàÐÍ£º rabbit polyclonal

¼¼Êõ¹æ¸ñ

Background:

Serine¡ªpyruvate aminotransferase is an enzyme that in humans is encoded by the AGXT gene. This gene is expressed only in the liver and the encoded protein is localized mostly in the peroxisomes, where it is involved in glyoxylate detoxification. Mutations in this gene, some of which alter subcellular targetting, have been associated with type I primary hyperoxaluria. Defects in AGXT are the cause of hyperoxaluria primary type 1 (HP1), also known as primary hyperoxaluria type I (PH1) and oxalosis I. HP1 is a rare autosomal recessive inborn error of glyoxylate metabolism characterized by increased excretion of oxalate and glycolate, and the progressive accumulation of insoluble calcium oxalate in the kidney and urinary tract.

Applications:

ELISA, WB

Name of antibody:

AGXT

Immunogen:

Synthetic peptide of human AGXT

Full name:

Alanine-glyoxylate aminotransferase

Synonyms£º

AGT; PH1; SPT; AGT1; SPAT; TLH6; AGXT1

SwissProt:

P21549

ELISA Recommended dilution:

2000-5000

WB Predicted band size:

43 kDa

WB Positive control:

Human fetal liver tissue and hepg2 cells

WB Recommended dilution:

500-2000






¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿


¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿